emupertinib   Click here for help

GtoPdb Ligand ID: 13742

Synonyms: example 37 [WO2020166680A1]
Compound class: Synthetic organic
Comment: The chemical structure for emupertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. This is one of the EGFR inhibitor compounds claimed in Taiho Pharma patent WO2020166680A1 [1]. Analysis of Tiaho's decalred pipeline, suggests that emupertinib may be the INN for their candidate TAS3351 (intended for NSCL, but target not declared), as it can't be TAS6417 which has a different chemical structure and is assigned the INN zipalertinib. We await formal declaration of any name-to-structure association.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 120.16
Molecular weight 514.58
XLogP 0.8
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C#CC1=C(C2=CN=C3C=CC=CC3=C2)C4=C(N=CN=C4N)N1C56CCC(CC5)(C6)NC(=O)C7=CN=C(C)C=N7
Isomeric SMILES CC1=CN=C(C=N1)C(=O)NC23CCC(C2)(CC3)N4C(=C(C5=C(N=CN=C54)N)C6=CC7=CC=CC=C7N=C6)C#C
InChI InChI=1S/C30H26N8O/c1-3-23-24(20-12-19-6-4-5-7-21(19)34-14-20)25-26(31)35-17-36-27(25)38(23)30-10-8-29(16-30,9-11-30)37-28(39)22-15-32-18(2)13-33-22/h1,4-7,12-15,17H,8-11,16H2,2H3,(H,37,39)(H2,31,35,36)
InChI Key NKRUHCMBVJSNAB-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Yamamoto F, Mizutani T, Kasuga H, Fuchida Y, Hara S, Kobayakawa Y, Ogino E. (2020)
7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative.
Patent number: WO2020166680A1. Assignee: Taiho Pharmaceutical Co., Ltd.. Priority date: 14/02/2020. Publication date: 20/08/2020.